Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 633 • 2015 ACR/ARHP Annual Meeting
Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹, Leah Medrano² and Mara McAdams-Demarco³, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Anti-centromere antibodies (ACA) define a subgroup of Sjögren’s syndrome (SS) patients who are often older, have more frequent Raynaud’s phenomenon, and a lower frequency…
Abstract Number: 1253 • 2015 ACR/ARHP Annual Meeting
Identification and Validation of Novel Putative Salivary Proteomic Biomarkers in Sjögren’s Syndrome and Different Disease Subsets
Chiara Baldini¹, Daniela Martini¹, Nadia Ucciferri², Silvia Rocchiccioli², Letizia Mattii³, Antonietta Raffaella Maria Sabbatini³, Francesca Sernissi¹, Francesco Ferro¹, Nicoletta Luciano¹, Leonardo Lorenzini¹, Marta Mosca⁴, Stefano Bombardieri¹ and Antonella Cecchettini³, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Institute of Clinical Physiology, Pisa, Italy, Pisa, Italy, ³Department of Clinical and Experimental Medicine, University of Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Pisa, Italy
Background/Purpose: Salivary proteomics has recently appeared as a promising tool for the identification of novel diagnostic biomarkers for primary Sjögren’s syndrome (SS). However, to date…
Abstract Number: 2795 • 2015 ACR/ARHP Annual Meeting
Fatigue in Primary Sjögren’s Syndrome: Clinical, Laboratory, Psychometric and Biological Associations
Theofanis Karageorgas¹, Sofia Fragkioudaki², Adrianos Nezos³, Dimitris Karaiskos⁴, Clio Mavragani⁵ and Haralampos M. Moutsopoulos⁶, ¹Clinical Immunology and Rheumatology, "Attikon" University Hospital of Athens, Athens, Greece, ²Physiology, Medical School of Athens, Department of Physiology, Athens, Greece, ³Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ⁴Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁵Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ⁶Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece
Background/Purpose: To identify independent predictors of fatigue in primary Sjogren’s Syndrome (pSS) patients taking into account clinical, laboratory and psychological features and to explore the…
Abstract Number: 634 • 2015 ACR/ARHP Annual Meeting
Big Data International Primary Sjögren Syndrome Registry: Baseline Characterization and Diagnostic Approach in 6047 Patients Fulfilling the 2002 AE Criteria
Pilar Brito-Zerón¹, Soledad Retamozo^1,2, Margit Zeher³, Astrid Rasmussen⁴, Elke Theander⁵, Jacques Gottenberg⁶, Chiara Baldini⁷, Luca Quartuccio⁸, Roberta Priori⁹, Valeria Valim¹⁰, Marika Kvarnström¹¹, Aike Kruize¹², Gabriela Hernandez-Molina¹³, Elena Bartoloni-Bocci¹⁴, Sonja Praprotnik¹⁵, David A. Isenberg¹⁶, Gunnel Nordmark¹⁷, Michele Bombardieri¹⁸, Yasunori Suzuki¹⁹, Roser Solans²⁰, Roberto Giacomelli²¹, Daniel S. Hammenfors²², Steven E. Carsons²³, Hendrika Boostma²⁴, Cristina F. Vollenweider²⁵, Fabiola Atzeni²⁶, Kathy Sivils²⁷, Thomas Mandl²⁸, Salvatore De Vita²⁹, Marie Wahren-Herlenius¹¹, Mitsuhiro Kawano³⁰, Roberto Gerli³¹, Arjan Vissink³², Johan G. Brun³³, Virginia Trevisani³⁴, Jorge Sánchez-Guerrero³⁵, Xavier Mariette³⁶, Manuel Ramos-Casals¹ and on behalf of the EULAR-SS Task Force, ¹Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³University of Debrecen, Debrecen, Hungary, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Skåne University Hospital Malmö, Lund University, Malmo, Sweden, ⁶Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁷Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ⁸Clinic of Rheumatology, Department of Medical and Biological Sciences (DSMB), Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ⁹Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ¹⁰Rheumatology, Universidade Federal do Espírito Santo, Vitória, Brazil, ¹¹Department of medicine, Rheumatology unit, Karolinska Institutet, Stockholm, Sweden, ¹²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ¹⁴Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁵Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁶Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁷Medical Sciences, Uppsala University, Uppsala, Sweden, ¹⁸Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ¹⁹Kanazawa University Graduate School of Medicine, Kanazawa, Japan, ²⁰Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain, ²¹University of L'Aquila, L'Aquila, Italy, ²²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²³Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, ²⁴University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²⁵Rheumatology, German Hospital, Buenos Aires, Argentina, ²⁶Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁸Dept of Rheumatology, Skåne University Hospital Malmö, Lund University, Malmo, Sweden, ²⁹Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ³⁰Division of Rheumatology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, ³¹University of Perugia, Perugia, Italy, ³²Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³³Haukeland University Hospital, Bergen, Norway, ³⁴Health Evidence Based, Universidade Federal de São Paulo, Sâo Paulo, Brazil, ³⁵Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, ³⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: To analyse the epidemiological, clinical and immunological characteristics at diagnosis of the largest international cohort of patients diagnosed with primary Sjögren syndrome (SS) according…
Abstract Number: 1262 • 2015 ACR/ARHP Annual Meeting
Epigenome-Wide DNA Methylation Patterns Associated with Fatigue in Primary Sjögren’s Syndrome
Katrine B Norheim¹, Juliana Imgenberg-Kreuz², Kristin Jonsdottir³, Emiel Janssen⁴, Ann-Christine Syvänen², Johanna K Sandling², Gunnel Nordmark⁵ and Roald Omdal⁶, ¹Dept of Internal Medicine, Clinical immunology Unit, Stavanger, Norway, ²Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³Dept. of Pathology, Stavanger University Hospital, Stavanger, Norway, ⁴Dept. of Pathology, Stavanger university Hospital, Stavanger, Norway, ⁵Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁶Department of internal medicine, Clinical Immunology unit, Stavanger, Norway
Background/Purpose: Chronic fatigue is a common, often disabling, and poorly understood phenomenon of many diseases. Recent studies indicate that epigenetic mechanisms may be involved in…
Abstract Number: 2796 • 2015 ACR/ARHP Annual Meeting
Elevated Serum Immunoglobulin G Is a Prognostic Factor for Progression of Interstitial Lung Disease in Primary Sjögren’s Syndrome
Eriko Ishioka¹, Katsuya Suzuki², Naoshi Nishina², Hidekata Yasuoka³, Kunihiro Yamaoka² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Lung involvement is a systemic manifestation of primary Sjögren's syndrome (pSS), however, the prevalence in pSS is various (9-75 %) and details are still…
Abstract Number: 635 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹ and Julius Birnbaum², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with Sjögren’s syndrome (SS) and negative SSA/SSB serology (ie. seronegative SS) have phenotypic characteristics different than seropositive ones, and thus may constitute a…
Abstract Number: 1358 • 2015 ACR/ARHP Annual Meeting
Detection of a Unique Viral Infection in Salivary Glands of Sjögren’s Syndrome Patients and Viral-Mediated Recapitulation of Disease in Vivo
Melodie Weller¹, Matthew Gardner¹, Zoe Bogus¹, Michael Smith¹, Elisa Astorri², Drew Michael¹, Changyu Zheng¹, Peter Burbelo³, Paul A. Wilson⁴, Zhennan Lai¹, Bill Swaim¹, Beverly Handelman¹, Sandra Afione¹, Michele Bombardieri² and John A. Chiorini¹, ¹Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³Clinical Dental Research Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁴National Intramural Database, Division of Enterprise and Custom Applications, Center for Information Technology, National Institutes of Health, Bethesda, MD
Background/Purpose: A viral infection is thought to be one of the triggers in the development of primary Sjögren’s syndrome (pSS). Multiple studies have shown stimulation…
Abstract Number: 2797 • 2015 ACR/ARHP Annual Meeting
Identification of Serum Biomarker for the Glandular Dysfunction of Primary Sjögren’s Syndrome
Ayumi Nishikawa¹, Katsuya Suzuki¹, Yoshiaki Kassai², Yuumi Gotou³, Takahiro Miyazaki⁴, Maiko Takiguchi⁴, Rimpei Morita⁵, Akihiko Yoshimura⁵ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Takeda Pharmaceutical Company, Fujisawa, Japan, ³Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan, ⁵Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by dry eye and mouth. Measurements of un-stimulated salivary flow and Schirmer’s test are…
Abstract Number: 2537 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracies of Sialography and Salivary Ultrasonography in Sjogren’s Syndrome Patients: A Meta-Analysis
Young Ho Lee¹ and Gwan Gyu Song², ¹Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, ²Div of Rheum, Dept of Int Medicine, Guro Hospital, Korea Univ College of Medicine, Seoul, South Korea
Background/Purpose Ultrasonography (US) may come to replace conventional invasive examinations in clinical practice. However, the diagnostic accuracy of salivary US has not been clearly compared…
Abstract Number: 1605 • 2014 ACR/ARHP Annual Meeting
Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus
Peter M. Izmirly¹, Robert M. Clancy², Melissa Munroe³, Sara Rasmussen², Amit Saxena^2,4, Jose U. Scher², Aikaterini Thanou⁵, Stan Kamp⁶, Joan T. Merrill⁷, Jill P. Buyon² and Judith James⁸, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mothers of children with neonatal lupus offer a unique opportunity to study the drivers and consequences of autoantibody production in the absence of ongoing…
Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting
Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Svein Joar A. Johnsen¹, Einar Gudlaugsson², Ivar Skaland², Emiel Janssen², Malin V. Jonsson³, Lars Helgeland⁴, Ellen Berget⁵, Roland Jonsson⁶ and Roald Omdal¹, ¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ²Stavanger University Hospital, Stavanger, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵University of Bergen, Bergen, Norway, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…
Abstract Number: 2536 • 2014 ACR/ARHP Annual Meeting
The Sjögren’s Syndrome Responder Index, a Data-Driven Combined Endpoint, Could Detect Biologics Efficacy
Divi Cornec¹, Valerie Devauchelle-Pensec², Xavier Mariette³, Sandrine Jousse-Joulin⁴, Jean-Marie Berthelot⁵, Aleth Perdriger⁶, Xavier Puéchal⁷, Véronique le Guern⁸, Jean Sibilia⁹, Jacques Gottenberg¹⁰, Laurent Chiche¹¹, Eric Hachulla¹², Pierre-Yves Hatron¹³, Vincent Goëb¹⁴, Gilles Hayem¹⁵, Jacques Morel¹⁶, Charles Zarnitsky¹⁷, Jean Jacques Dubost¹⁸, Raphaèle Seror¹⁹, Jacques-Olivier Pers²⁰, Emmanuel Nowak²¹ and Alain Saraux²², ¹Department of rheumatology and unit of immunology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ³rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ⁴Rheumatology, CHU Brest, Brest, France, ⁵Rheumatology, CHU Nantes (Nantes University Hospital), Nantes, France, ⁶Rhumatologie, Rennes, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹147 Boulevard Baille, CHU Marseille, Marseille, France, ¹²Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ¹³CHU Lille, Lille, France, ¹⁴Rheumatology, Amiens University Hospital, Amiens, France, ¹⁵CHU Bichat, Paris, France, ¹⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹⁷Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁸Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ¹⁹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²⁰CHU Brest, Brest, France, ²¹CIC, CHU Brest, Brest, France, ²²Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France
Background/Purpose Efficacy of rituximab remains debated in primary Sjögren’s syndrome (pSS), but that could be partly due to the absence of validated endpoint. To determine…
Abstract Number: 1329 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical and Serological Features of Childhood Sjögren Syndrome Based on the Presence or Absence of Parotitis
Jay Mehta¹, Namrata Singh² and Scott Lieberman³, ¹Pediatrics, Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, ²Medicine, University of Iowa, Iowa City, IA, ³Pediatrics (Division of Rheumatology), University of Iowa Children's Hospital, Iowa City, IA
Background/Purpose: Sjögren syndrome is a complex autoimmune disease that affects lacrimal and salivary glands with the potential to cause damage to other organs. Diagnosis of…
Abstract Number: 2534 • 2014 ACR/ARHP Annual Meeting
Ocular Surface Temperature in Early Sjogren’s Syndrome and Established Disease
Andreea Coca¹, Ranjini Kottaiyan², Mircea Coca³, Debbie Campbell⁴, Holly Hindman² and James Aquavella², ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Ophtalmology, University of Rochester, Rochester, NY, ³Ophtalmology, University of Texas Medical Branch, Galveston, TX, ⁴Allergy, Immunology and Rheumatology, Univerity of Rochester, Rochester, NY
Background/Purpose Due to a variety of factors it is challenging to make a definite diagnosis in the early stages of Sjögren’s syndrome (SS). The ocular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.